ArticleJournal of neuro-oncology2023

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.

Jonathan Weller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.